A B S T R A C T The present study demonstrates the existence on human peripheral blood lymphocytes of a saturable cell surface receptor for low density lipoprotein inhibitor (LDL-In), a subset of normal human serum low density lipoprotein (LDL) 
INTRODUCTION
Cell surface membrane receptors serve as specific recognition sites for the regulation of cellular metabolism by certain exogenous signals. Although a variety of molecules interact with surface receptors, serum lipoproteins have only recently been shown to participate in surface receptor-dependent bioregulatory phenomena. Low density lipoprotein (LDL),1 the first described bioregulatory lipoprotein, has been shown to regulate cholesterol biosynthesis in vitro (1, 2) . LDL, which binds with high affinity to specific cell surface membrane receptors, appears to be internalized by a process resembling endocytosis and subse(uently I Abbreviations used in this paper: BSA, bovine serum albumin; DS, Dulbecco's phosphate-buffered saline; E receptor, nonimmune lymphocyte receptors for SRBC; FCS, fetal calf serum; HDL, high density lipoprotein; LDL, low density lipoprotein; LDL-In, low density lipoprotein inhibitor; LPDS, lipoprotein-depleted serum; PBL, human peripheral blood lymphocytes; PBM, human peripheral blood mononuclear cells; PHA, phytohemagglutinin; RIF, rosette inhibitory factor; SRBC, sheep red blood cells.
transported to lysosomes where the cholesterol ester component of LDL is hydrolyzed and the resultant unesterified cholesterol released. This cholesterol then reduces the cellular biosynthesis of unesterified cholesterol by regulating the activity of a rate-controlling enzyme.
Independent studies of humoral factors that influence lymphocyte function have led to the recognition of two subsets of LDL that also possess bioregulatory properties, namely: (a) rosette inhibitory factor (RIF), and (b) low density lipoprotein inhibitor (LDLIn) . RIF, first discovered in some sera from individuals with hepatitis virus infection, is an inducible minor species of serum LDL capable of metabolically regulating the functional capacity of human thymusderived lymphocytes to bind to sheep red blood cells (SRBC) via the E receptor (3, 4) . RIF, which appears to possess an unusual apolipopeptide composition, binds with very high affinity to a limited number of lymphocyte surface receptors (RIF receptors) that are independent of the E receptor (3, 4) .
LDL-In was subsequently identified by us in normal human serum by its capacity to suppress human lymphocyte responses to mitogen and allogeneic cells in vitro (5) . We have suggested that LDL-In may represent a normal physiologic repressor of lymphocyte activation (6) . LDL-In that has been partially purified from whole LDL appears to represent a relatively minor species of serum LDL (5) . The biological effect of human LDL-In on lymphocytes is not species specific because isolated LDL-In suppresses both murine mixed lymphocyte reactions (6) and the primary generation of murine cytotoxic T cells in vitro (7) . Administration of less than 10 pmol of human LDL-In to mice induces a significant suppression of the primary cytotoxic T-cell response (7) . The bioregulatory effects of LDL-In are temporally dependent and only a transient exposure of lymphocytes to LDL-In is required to suppress their subsequent stimulation by lectins or allogeneic cells (5, 6) . Furthermore, the regulatory effects of LDL-In are selective in that LDL-In appears to influence only the primary inductive events required for lymphocyte stimulation (5) (6) (7) .
Recent evidence has identified the lymphocyte rather than the macrophage as the primary target of LDL-Inmediated immunoregulation (8) , and it is now appropriate to ask whether or not a cellular receptor is involved in the initial steps of LDL-In-mediated regulation. This study is addressed to the interaction of LDL-In with human lymphocytes and the identification ofa discrete saturable cell surface receptor for this immunoregulatory molecule. METHODS Cells. Peripheral blood mononuclear cells (PBM) from normal donors were isolated from heparinized venous blood by a modification of the method of Boyum (9) . Blood was diluted with an equal volume of RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.), and 10-ml aliquots layered onto 3 ml of Ficoll-Hypaque (1.074 g/cm3; Pharmacia Fine Chemicals, Piscataway, N. J.). After centrifugation at 2,260 g (at the interface) for 6 min at 20°C, the mononuclear cells were harvested from the interface, mixed with 20 ;tl of 1% washed homologous carrier erythrocytes, washed three times with RPMI-1640, and recovered by centrifugation at 1,200 g for 5 min at 20°C. Cells were resuspended in complete medium consisting of RPMI-1640 supplemented with 100 U/ml penicillin, 50 ,ug/ml streptomycin, 2 mM glutamine, and 10% (vol/vol) fetal calf serum (FCS). Yields of >75% that contained 83-90% lymphocytes, 10-15% monocytes, and <2% polymorphonuclear leukocytes were obtained. Viability was >98% in all cases.
Peripheral blood lymphocytes (PBL) to be used in the binding assays were prepared from PBM resuspended to a final concentration of 2 x 106/ml in complete medium containing 10% (vol/vol) lipoprotein-depleted serum (LPDS). 20-ml aliquots were then transferred to plastic tissue culture flasks with a 75-cm2 growth area (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.) and maintained at 37°C in humidified 5% CO2 in air. When present, the sterols, cholesterol and 25-hydroxycholesterol (Steraloids, Inc., Pawling, N. Y.) were added in absolute ethanol (final volume 0.5% or less). Lymphocytes were recovered after 48-72 h of culture. Viability was >96% with more than 98% of the cells identified as lymphocytes by cytologic criteria and the peroxidase (10) (11) . LDL-In, purified >70,000-fold relative to serum proteins, was purified from pooled normal human serum by dextran sulfate precipitation followed by density gradient ultracentrifugation in NaCl and molecular exclusion chromatography on a 2.5 x 85-cm column of Biogel A-15 (200-400 mesh; BioRad Laboratories, Richmond, Calif.) (5) . As described previously, LDL-In is characterized by a mean buoyant density lower than the peak density of total LDL and as currently isolated represents a subset of serum whole LDL (5) . The absolute degree of purity relative to whole LDL cannot be assessed in the absence of a quantitative means of analysis for LDL that is not LDL-In; however, preparations are purified 25-to Iodination. 100 ,ug of LDL or LDL-In were labeled with 2 mCi of 1251 (17 Ci/mg; New England Nuclear, Boston, Mass.) using critically limited oxidation with 5 ,ug of chloramine T (14) . About 4% (3.0-4.8%) of 1251 was incorporated. After extensive dialysis against lipoprotein buffer and determination of protein concentration, the radiolabeled lipoproteins were chromatographed on a 1.5 x 30-cm column of BioGel A-5, 200-400 mesh (BioRad Laboratories) in lipoprotein buffer containing 1% bovine serum albumin (BSA); and the radiolabeled lipoproteins recovered in the void peak. Greater than 94% of the radioactivity was precipitated by incubation for 30 min in 15% trichloroacetic acid at 90°C, 7% or less was extracted into 20 vol of 3:1 ethanol-ether (15) . More than 95% of the trichloroacetic acid-soluble radioactivity was identified as free iodide by chloroform extraction according to Bierman et al. (16) . Mock-iodinated LDL-In, prepared using the same number of moles of iodide ions containing trace 1251 (sp act 0.17 Ci 1251/mg), was similarly characterized.
Lymphocyte-suppressive activity. Lipoprotein preparations were assayed for biological activity by measuring the suppression of phytohemagglutinin (PHA)-induced lymphocyte responses in vitro as described previously (5, 8 Lipoprotein binding assays. The binding of LDL-In to PBL was analyzed by a modification of the techniques of Ho et al. (2) . After cultivation for 48 h in complete RPMI-1640 medium containing 10% (vol/vol) LPDS, the lymphocytes were harvested by centrifugation at 1,200 g for 5 min at 20°C. Carrier erythrocytes were lysed by incubation for 30 min at 37°C in 0.14 M NH4Cl, 0.015 M tris, pH 7.2; and the lymphocytes washed twice in ice-cold Dulbecco's phosphate-buffered saline (DS) containing 100 ,uM CaCl2 and 20 mg/ml bovine serum albumin (DS-BSA). Subsequent steps were carried out at 4°C unless otherwise noted. Portions of the cell suspension (4-5 x 106 cells) were added to 1.2-ml silicone-coated polycarbonate tubes, centrifuged for 2 min at 1,000 g and the supernate discarded. Assays were conducted in duplicate at a final reaction volume of 100 j.d, which included the cells, 50 IlI DS-BSA, 1251-LDL, or 1251-LDL-In in DS, and competing unlabeled lipoprotein in DS when present. Binding assays performed to assess the effects on the lymphocytes of prior incubation in the presence of 24-hydroxycholesterol and cholesterol were carried out in plastic tissue culture flasks with a 25-cm2 growth area (Falcon Plastics) for 5 h at 37°C. These assays were conducted in duplicate at a final reaction volume of 2.0 ml, which included the cells at 2 x 106/ml in complete medium containing 10% (vol/vol) LPDS, and 50 ul of the labeled ligand in DS. Labeled and unlabeled lipoprotein preparations were centrifuged at 7,000 g for 5 min immediately before use. After incubation, the cells were collected by the addition of 1.0 ml of DS-BSA and centrifugation at 7,000 g for 5 min. The cell pellet was washed with 1.0 ml of DS-BSA, immediately centrifuged at 7,000 g for 3 min, resuspended in 100 ,ul of DS-BSA, layered onto a second tube containing 1.0 ml of 100% FCS, and recentrifuged at 7,000 g for 5 min. The radioactivity of the recovered cell pellets was determined in a gamma counter, and the pellets hydrolyzed by incubation overnight at 370C with 0.5 ml 0.1 N NaOH. The protein content was determined by the method of Lowry et al. (12) LPDS. The cells were incubated at 37°C in .5% CO2 in air. Aliquots of control and trypsin-treated cells were removed at the times indicated and assayed f'or their capacity to bind 125I-LDL-In and to form E rosettes. Viability was >94%, and 87% of the cells were recovered.
E receptor assay. Human T lymphocytes positive f'or E receptors were assayed by adherence to neuraminidasetreated SRBC (4). The PBL (1 x 106 in 0.5 ml) were washed twice in Puck's saline G by centrifugation at 1,000 g for 2 min. The washed pellet was mixed with 0.1 ml of a 1% suspension of' neuraminidase-treated SRBC, immediately centrifuged at 400 g for 5 min, and maintained at room temperature for 15 min. Wet mounts were prepared by adding 5 ,ul of 0.02% trypan blue, gently resuspending the cells and transferring them to a microslide. 400 viable lymphocytes were counted and scored as positive if three or more SRBC adhered to each lymphocyte.
Immunofluorescent assays. The presence of' LDL or LDL-In on the surface of viable PBL grown in LPDS after incubation with up to 280 ,ug/ml LDL-In f'or 4 and 24 h at 4°or 37°C was assayed: (a) by direct immtinofluorescent antibody assays using fluorescein isothiocyanatecoupled IgG from high titer antiserum produced by immunizing rabbits with LDL-In, and (b) by indirect assays using either rabbit antisera to LDL or LDL-In, or fluorescein isothiocyanate-coupled rabbit antisera to LDL-In followed by fluorescein isothiocyanate-coupled IgG fraction of' goat anti-rabbit IgG. Direct assays were perf'ormed at 40C, and reagents prepared as described for surface immunoglobulin (4). Indirect assays employed 30-min reaction periods at 40C for both the first and the second antibody. The sensitivity of the assays was determined by coupling LDL-In to Affi-Gel 10 beads (BioRad Laboratories) which were substituted f'or the cells in preliminary experiments. Beads conjugated with as few as 86 molecules of LDL-In/ ,um2 area of bead surface were positive using the indirect assays. This provides an estimated sensitivity of <13,000 molecules per lymphocyte based on an observed mean diameter of 7.1 ,um and a relatively smooth surface at 4°C to yield a mean surface area of 160 Am2/lymphocyte.
Calculations and statistical analyses. was 6 ,ug/ml, which was equal to that of noniodinated LDL-In. The specific suppressive activity of total LDL isolated by sequential ultracentrifugation is also shown in Fig. 1 , and gave 50% suppression at a 24-fold lower specific activity (150 ,ug/ml).
Characterization of the binding reaction. XVhen LDL-In containing 0.98 atoms of 1251 per molecule was incubated with human PBL, initial rapid binding occurred within approximately 5 min. This was followed by a second and slower binding phase. For example, when 14.5 ug/ml of 1251-LDL-In was incubated with 4-5 x 106 PBL/ml, at 4°C, equilibrium conditions were achieved within 40-50 min (Fig. 2) . In contrast, at 37°C equilibrium conditions were not observed within an equivalent time period. Instead, binding progressed linearly for more than 24 h (not shown). The probability that the 1251-LDL-In was internalized after binding to the cell, rather than accumulated at the surface, was suggested by direct and indirect immunofluorescent assays. After incubating the cells with 280 ,ug/ml LDL-In at 370 or 4°C for 4 was added and the tubes incubated at either 4°or 37°C for the times indicated after which the total amount of 125I-LDL-In bound to the cells was determined as described in Methods.
treated cells regenerated the ability to form E rosettes upon subsequent culture. We used the same conditions to demonstrate removal and regeneration of the capacity to bind 125I-LDL-In. After trypsin treatment, E receptor-positive lymphocytes decreased 100% from 53.4+3.5% to 0, and the binding of 1251-LDL-In de- When cultured in complete media containing 10% LPDS, these same lymphocytes regenerated both receptors; however, the rate of regeneration differed significantly (Fig. 3 ). An estimated half regeneration time of 3.6 h was calculated for LDL-In receptor in contrast to 13.6 h for E receptor. Binding affinity. To estimate the number of LDLIn receptors per lymphocyte, the binding of 125I-LDLIn by lymphocyte receptors at 4°C was permitted to reach equilibrium at a series of 125I-LDL-In concentrations between 5.3 and 26.6 ,ug/ml. The number of receptors per lymphocyte was then calculated from a modified Scatchard plot (Fig. 4) . Extrapolation to saturation (bound/free = 0), gave an estimate of 22.12 ng LDL-In protein bound per 5 x 106 lymphocytes. Assuming that the receptor is a single molecular complex or molecule capable of interacting with LDL-In in an equimolar fashion, the number of saturable receptor sites per lymphocyte was estimated at 4,860+456. Half saturation of this calculated number of receptors occurred at a free LDL-In concentration of 68.2 nM. From these values the mean binding affinity (K) was estimated to be approximately 1.47 x 107 liters/mol. Binding specificity. The specificity of binding was evaluated in sequential competitive inhibition or blocking experiments we refer to as prior site occupancy studies. An unlabeled ligand was incubated with the lymphocytes at 4°C for 60 min and without washing, then incubated for an additional 60 min after the same or the alternate radiolabeled ligand had been added. The validity of these experiments in determining binding site specificity is based upon the assumption that the first ligand, if bound to the cell, will remain associated and will not be released during incubation with the radiolabeled second ligand. Stability of the association of cell-bound 1251-LDL-In at 4°C, and the rate of its exchange with free LDL-In was therefore determined. As shown in Table IL, Because the rate of exchange between bound and free ligand was insignificant, the dissociation constant is extremely high, and the use of prior site occupancy appears to represent a valid approach to determining receptor specificity. When PBL were incubated with LPDS or purified HDL (5.8 mg/ml) for 60 min at 4°C, the subsequent binding of 1251-LDL-In was not diminished (Fig. 5a ). Homologous LDL-In inhibited the subsequent binding of 125I-LDL-In, and 50% inhibition was observed at 67 ,ug/ml. An equal concentration of total LDL was without effect (Fig. 5a) . In fact, a 13.4-fold greater concentration of total serum LDL (900 ,ug/ml) was required to occupy 50% of the 125I-LDLIn binding sites. The inhibition slopes for LDL (-17.4) and LDL-In (-19.7) (Fig. 5a) were not statistically different (P = 0.4). This is consistent with the concept of prior site occupancy by molecules of similar affinity for the same binding site, but by molecules that are present at different concentrations. (16 ,uglml) in the lipoprotein-deficient preincubation medium has been demonstrated (20) (2) (3) (4) (5) (6) (7) (8) (9) (10) ,ug/ml) and cholesterol (16 ,tg/ml) resulted in marked attenuation of the binding of 1251-LDL. However, these same conditions had no discernible effect on the quantity of 125I-LDL-In bound by these lymphocytes. (Table I ). These findings are particularly relevant in light of the recent observations by Dana et al. (23) that the specific binding of 125I-LDL to nonsiliconized glass is Ca++ independent. The calcium requirement is also dependent upon the concentration of added 1251-LDL-In, and is typified by the observation that at higher LDL-In concentrations the calcium dependence is less evident (data not shown). Lymphocytes readily bind LDL-In at concentrations of 2-10 ,g/ml even though albumin is present in excess (400-fold by mass or 136,000-fold by molar concentration) in the reaction medium, and the cells are subsequently sedimented through FCS. This suggests that binding is specific and not simply a nonspecific adsorption phenomenon.
Finally, binding of LDL-In is saturable under conditions that arrest the metabolic activities of the cell, i.e., low temperature. The observation that saturable binding could not be demonstrated at 370C and that there is a progressive linear association of LDL-In with the lymphocytes suggests internalization similar to that described for LDL (2, 24) . This interpretation is further supported by our failure to detect LDL-In accunmulation at the surface of viable cells. Although at least 10,000 molecules can be anticipated to bind per cell within the 1st h (estimated from data in Fig. 2) , neither LDL nor LDL-In could be visualized bv immunofluorescence. 24 h later, when more than 100,000 molecules ought to be detectable per cell, LDL-In could still not be visualized at the surface of viable cells.
Cell-associated LDL-In remained at all tinmes below the limits ofvisualization which we estimate at < 13,000 molecules/cell. Metabolic-dependent internialization of receptor bound '25I-LDL-In such as described for LDL (2, 24) could reasonably account for these observations, and is the subject of a currenit studv of the cellular catabolism of LDL-In. More Second, all LDL molecules or a subset may be bound less efficiently by the LDL-In binding site. Because LDL contains LDL-In (5), a comparison of the binding curves (Fig. 5a) suggests that the concentration required for inhibition of binding of the I25j-LDL-In ligand would occur if 7.3% of the LDL preparation were LDL-In. This estimated percentage does not differ greatly from the 4% LDL-In content of LDL required to account for the immunosuppressive properties of this preparation of LDL (Fig. 1) . Further evidence that the LDL-In present in total LDL may be responsible for the observed binding of LDL to the 125I-LDL-In receptor is the statistically significant identity (P < 0.005) of the inhibition slopes of LDL and LDL-In (Fig. 5a) .
If LDL-In is a discrete subset of LDL, then is the receptor responsible for the binding of LDL-In identical to the LDL receptor or are there two distinct and independent receptors on PBL? If only one receptor exists, then according to the results of the prior site occupancy experiments (Fig. 5a ), LDL-In represents a selected subset of LDL molecules with an affinity greater than whole LDL for the LDL receptor. In this case, LDL-In should also occupy this single receptor more efficiently when the radiolabeled ligand is 1251_ LDL. If there are two independent receptors, one for LDL and another for LDL-In, then LDL-In would either not compete for the LDL receptor or, at the very least, compete less efficiently for the LDL receptor. A distinction between a one-vs. a two-receptor hypothesis is possible from analysis of the binding of LDL and LDL-In to the 1251-LDL receptor (Fig. 5b) . LDL-In does not inhibit the subsequent binding of 1251-LDL to the LDL receptor as efficiently as LDL. These results support a two-receptor hypothesis. However, LDL-In is capable of saturating LDL receptor sites (Fig. 5b) , and complete saturation is achieved at very high concentrations (10 mg/ml). Ifthe LDL-In preparation used in these experiments contained only 4% LDL, and this LDL contaminant were responsible for occupancy of the LDL receptor, the slopes would be identical. The lack of identity suggests that LDL-In might also be bound at lower affinity by the LDL receptor.
The net binding and the blocking by each of the lipoproteins are tabulated for comparison in Table IV . This supports the hypothesis that just as the two ligands, LDL and LDL-In, do not appear to be identical, their respective binding sites on the lymphocyte surface are also not strictly identical. The hypothesis that one receptor binds both ligands is inconsistent with the observation that at a concentration of 400 ,ug/ ml, LDL-In completely blocks the binding of 1251-LDLIn; but at the same concentration permits 84% occupancy of the 1251-LDL binding sites (Table IV) . Similarly, LDL at 400 ug/ml has completely blocked the binding of 1251-LDL, but still permits 64% occupancy of the 1251-LDL-In binding sites (Table IV) . We conclude from this that at least two discernible lipoprotein receptors exist on the lymphocyte, each of which is capable of binding a different subset of normal human serum LDL. This initial conclusion is supported by two additional observations which serve to further distinguish between LDL and LDL-In receptors. First, the enhanced binding of LDL-In that results from preincubation of the cells in LPDS is not abrogated by the addition of 25-hydroxycholesterol and cholesterol to the preincubation medium as is the LDL binding (Table III) It is of interest that the biological activity of RIF at 20 ng/ml, the immunoregulatory species of serum LDL induced by hepatitis virus infections (3, 4) , is the same whether it is assayed in the presence of serum or not. Although normal serum contains a 105-106 M excess of LDL, and a 103-105 M excess of LDL-In, it does not diminish the binding of RIF. This leads us to suggest that neither LDL nor LDL-In interact with the previously described RIF receptor. We therefore propose that at least three independent surface membrane receptors for LDLs may exist on lympho-
